#Interphex opens its doors next week in New York and we will be there. This year we have something really BIIIIIIIIIIG with us. Have a look and try it out yourself! #pharma #Lifescience #BelimedLifeScience
Belimed Life Science’s Post
More Relevant Posts
-
The success of Day 1 at the MarketsandMarkets Biomarker and Companion Diagnostics Conference - EU Edition wouldn't have been possible without the generous support of our sponsors! We're grateful to have Predicine | Proteome Sciences plc | EpigenDx, Inc. | Biognosys | Sengenics | SomaLogic on board. Their contributions have been pivotal in creating a platform for knowledge exchange. Stay tuned for more insights and discussions on Day 2! #biomarker #biomarkervalidation #companiondiagnostics #healthcare #pharma #realworldevidence #healthcaretechnology #marketsandmarkets #ConferenceRegistration #BiomarkerConference #CompanionDiagnostics
-
Thoughts on this? >> BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #productmarketing #biotech
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #biotech #healthcare
BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial
https://endpts.com
-
Roche makes four pipeline changes on back of trial failures, but sees path ahead for three therapies >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #pharmaceutical #healthcare
Roche makes four pipeline changes on back of trial failures, but sees path ahead for three therapies
https://endpts.com
-
Targeting specific #subpopulations in clinical trials can reveal crucial insights. In our latest blog, Jim Bolognese discusses three key hypotheses for trials targeting specific subpopulations and different testing strategies. 👉 Learn more: https://hubs.ly/Q02Bkwxr0 #ClinicalTrials #Subpopulations #Biomarkers #HypothesisTesting #StatisticalPower #TrialDesign #Pharma #Biotech
-
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Roche makes four pipeline changes on back of trial failures, but sees path ahead for three therapies >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare
Roche makes four pipeline changes on back of trial failures, but sees path ahead for three therapies
https://endpts.com
-
Join us at booth 514 at #IFPAC2024 happening right now! Our experts are ready to chat with you and answer all your questions. Come say hello and get to know more about us and our partners Phyllon GmbH and InSilicoTrials. #pharma #continuousmanufacturing #OCT #ParticleSimulation #ProcessControl
-
-
Thoughts on this? >> Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #productmarketing #biotech
Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew
https://endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Akero returns with more MASH data to back PhIII FGF21 analog drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #pharmaceutical #productmarketing
Akero returns with more MASH data to back PhIII drug, touts fibrosis response rate
https://endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #pharma #healthcare
Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew
https://endpts.com
Inhaber u. Geschäftsführer bei KOSSMANN - EDELSTAHL GmbH
3mogood Luck !